Treatment shortening of drug-sensitive pulmonary tuberculosis using high-dose rifampicin for 3 months after culture conversion (Hi-DoRi-3): a study protocol for an open-label randomized clinical trial
暂无分享,去创建一个
S. Hahn | J. Yim | D. Jeon | Ji Yeon Lee | Y. Kang | Yong-Soo Kwon | J. Mok | Jung-Kyu Lee | N. Kwak | Jiwon Park | Ji Yeon Lee | Youngmok Park | B. Kwon | Jae Ho Lee | Hyung-Jun Kim | Kyung Jong Kim | Young Ran Kim | Minkyoung Cheon | Young Ae Kang
[1] H. Kim,et al. Evaluating the impact of the nationwide public–private mix (PPM) program for tuberculosis under National Health Insurance in South Korea: A difference in differences analysis , 2021, PLoS medicine.
[2] John L. Johnson,et al. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis. , 2021, The New England journal of medicine.
[3] Versione,et al. Common Terminology Criteria for Adverse Events , 2020, Definitions.
[4] W. Hoefsloot,et al. High-dose rifampicin in tuberculosis: Experiences from a Dutch tuberculosis centre , 2019, PloS one.
[5] Robin J. Svensson,et al. Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations , 2018, The Journal of infectious diseases.
[6] Robin J. Svensson,et al. The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[7] A. Diacon,et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial , 2017, The Lancet. Infectious diseases.
[8] S. Birch,et al. Does treatment collection and observation each day keep the patient away? An analysis of the determinants of adherence among patients with Tuberculosis in South Africa. , 2016, Health policy and planning.
[9] D. Mitchison,et al. High-dose rifampicin kills persisters, shortens treatment duration, and reduces relapse rate in vitro and in vivo , 2015, Front. Microbiol..
[10] A. Diacon,et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. , 2015, American journal of respiratory and critical care medicine.
[11] A. Crook,et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. , 2014, The New England journal of medicine.
[12] B. D. de Jong,et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. , 2015, The New England journal of medicine.
[13] P. Butcher,et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. , 2014, The New England journal of medicine.
[14] W. Mackenzie,et al. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. , 2014, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[15] A. Diacon,et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] K. Steingart,et al. Higher-dose rifampin for the treatment of pulmonary tuberculosis: a systematic review. , 2011, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[17] G. Drusano,et al. Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.
[18] E. Kantharaj,et al. Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[19] D. Mitchison,et al. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[20] Jae Ho Lee,et al. Substitution of ethambutol with linezolid during the intensive phase of treatment of pulmonary tuberculosis: a prospective, multicentre, randomised, open-label, phase 2 trial. , 2019, The Lancet. Infectious diseases.
[21] J. Yim,et al. Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis. , 2016, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[22] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..